WBR0375

Jump to navigation Jump to search
 
Author [[PageAuthor::Rim Halaby, M.D. [1], Alison Leibowitz [2] (Reviewed by Alison Leibowitz)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pathology
Sub Category SubCategory::Renal
Prompt [[Prompt::A 68-year-old Caucasian male, with a significant history of alcoholism, presents to the ER with an altered mental status and is unable to provide further history. Upon physical examination you observe fetor hepaticus, spider nevi, gynecomastia, and that his stomach is severely distended with shifting dullness. Following appropriate work-up, you diagnose him with hepatic cirrhosis and closely follow the standard treatment for his condition. Upon discharge, you prescribe the patient with spironolactone, for moderate ascites. The patient should be monitored for which of the following electrocardiogram (ECG) finding after initiation of spironolactone?]]
Answer A AnswerA::Two independent rhythms of P and QRS complexes
Answer A Explanation AnswerAExp::Third degree AV block is not commonly associated with spironolactone therapy. AV blockade is commonly seen in patients receiving beta blockers and calcium channel blockers.
Answer B AnswerB::“Saw tooth” appearance
Answer B Explanation AnswerBExp::“Saw tooth” appearance is the characteristic description of atrial flutter. Spironolactone is not commonly associated with atrial flutter.
Answer C AnswerC::Peaked T waves
Answer C Explanation AnswerCExp::Peaked T waves on ECG is characteristic of hyperkalemia, a common side effect of spironolactone therapy.
Answer D AnswerD::ST-segment elevation in leads I and aVL
Answer D Explanation AnswerDExp::ST-segment elevation is seen in myocardial infarction
Answer E AnswerE::Prolonged PR interval
Answer E Explanation AnswerEExp::Prolonged PR interval is characteristic of first degree AV block. Spironolactone does not commonly cause first degree AV blockade.
Right Answer RightAnswer::C
Explanation [[Explanation::Spironolactone, a competitive aldosterone receptor antagonist, is an effective treatment for patients with severe heart failure and ascites due to hepatic failure. Following initiation of spironolactone therapy, serum potassium concentrations should be periodically measured, monitoring for hyperkalemia, a common adverse reaction. Hyperkalemia is a potential side effect of spironolactone therapy, resulting from the inhibition of aldosterone’s physiologic activity, the excretion of potassium (often, spironolactone is described as a “potassium-sparing” diuretic). A typical ECG finding in patients with hyperkalemia is peaked T waves.

Educational Objective: Spironolactone, a competitive aldosterone receptor antagonist, is an effective treatment for patients with hepatic failure and ascites. Hyperkalemia is a common side effect of spironolactone therapy, manifesting with peaked T waves on ECG.
References: Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011;7:353-363.

Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17(10):1237-1248.]]

Approved Approved::Yes
Keyword
Linked Question Linked::
Order in Linked Questions LinkedOrder::